Stay updated with breaking news from Activity Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm...
Characterizing the clinical presentation, factors associated and determining disease severity among participants with Rheumatoid Arthritis. Read more
Here’s what I learned and concluded after my five-week Oura Ring trial.
Here’s what I learned and concluded after my five-week Oura Ring trial.
Study IDs factors predicting response to TNF inhibitors